Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Roncal, C. (Carmen) | - |
dc.creator | Orbe, J. (Josune) | - |
dc.creator | Rodriguez, J.A. (José Antonio) | - |
dc.creator | Belzunce, M. (Miriam) | - |
dc.creator | Beloqui, O. (Óscar) | - |
dc.creator | Diez-Martinez, J. (Javier) | - |
dc.date.accessioned | 2011-11-14T10:59:36Z | - |
dc.date.available | 2011-11-14T10:59:36Z | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | Roncal C, Orbe J, Rodriguez JA, Belzunce M, Beloqui O, Diez J, et al. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res 2004 Jul 1;63(1):176-185. | es_ES |
dc.identifier.issn | 0008-6363 | - |
dc.identifier.uri | https://hdl.handle.net/10171/19656 | - |
dc.description.abstract | BACKGROUND: We examined the influence of the 4G/5G PAI-1 (plasminogen activator inhibitor) genotype on Angiotensin II (Ang II)-induced PAI-1 expression by human endothelial cells (HUVEC) in the presence and absence of AT1-receptor blocker losartan, and screened for this polymorphism in relation to plasma PAI-1 and arterial pressure in apparently healthy subjects. METHODS AND RESULTS: Genotyped cultured HUVEC were incubated with Ang II (10(-8) M) with or without losartan up to 24 h. PAI-1 mRNA was determined in cell extracts and protein and activity assessed in supernatants and extracellular matrix (ECM). Ang II increased PAI-1 mRNA and activity in a genotype-dependent manner, higher values observed for 4G/4G HUVEC compared with 4G/5G and 5G/5G genotypes (p<0.05). Laser confocal microscopy and Western blot analysis showed increased PAI-1 protein within ECM in Ang II-stimulated cultures. PAI-1 expression and protein secretion induced by Ang II in 4G/4G HUVEC was completely inhibited by preincubation with 0.05 microM losartan (p<0.01), indicating an AT1-mediated effect. In a group of hypertensives homozygous for the 4G allele, PAI-1 antigen was significantly increased (51.0+/-10.1 ng/ml) compared with normotensives (28.3+/-4.0 ng/ml) and hypertensives carrying the 5G allele (p<0.05). CONCLUSIONS: The 4G/5G PAI-1 polymorphism determines the endothelial PAI-1 upregulation by Ang II and the inhibitory response to losartan. Analysis of PAI-1 genotypes may help identifying subgroups of hypertensives at higher cardiovascular risk. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press (OUP) | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | PAI-1 | es_ES |
dc.subject | Atherosclerosis | es_ES |
dc.subject | Polymorphism | es_ES |
dc.subject | Endothelium | es_ES |
dc.subject | Angiotensin-II | es_ES |
dc.subject | Arterial hypertension | es_ES |
dc.title | Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1016/j.cardiores.2004.03.023 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.